« Back to Record
Citation APA

Modi, S., Jacot, W., Iwata, H., Park, Y. H., Vidal, M. J. M., Li, W., Tsurutani, J., Ueno, N. T., Zaman, K., Prat, A., Papazisis, K., Rugo, H. H., Yamashita, T., Harbeck, N., Im, S. –., De Laurentiis, M., Pierga, J. Y. V. J., Wang, X., Gombos, A., Tokunaga, E., Orbegoso Aguilar, C., Yung, L., Xiao, F., Cheng, Y., & Cameron, D. A. (2025). Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nature medicine, 31(12), 4205-4213. doi:10.1038/s41591-025-03981-4


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/405023

Modi, S., Jacot, W., Iwata, H., Park, Y. H., Vidal, M. J. M., Li, W., Tsurutani, J., Ueno, N. T., Zaman, K., Prat, A., Papazisis, K., Rugo, H. H., Yamashita, T., Harbeck, N., Im, S. –., De Laurentiis, M., Pierga, J. Y. V. J., Wang, X., Gombos, A., Tokunaga, E., Orbegoso Aguilar, C., Yung, L., Xiao, F., Cheng, Y., & Cameron, D. A. (2025). Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nature medicine, 31(12), 4205-4213. doi:10.1038/s41591-025-03981-4